Clinical Trials Logo

Clinical Trial Summary

The investigators aim to evaluate a new potentially cost-effective approach to improving trichiasis surgery outcomes, perioperative topical anti-inflammatory therapy. The investigators hypothesize that adjunctive topical fluorometholone therapy following trichiasis surgery will reduce the risk of recurrent trichiasis. The rationale for this hypothesis is that interruption of inflammation postoperatively would reduce postoperative scarring, leading to better outcomes. As an initial step toward evaluating this modality, the investigators believe it to be necessary to evaluate topical corticosteroid therapy in a safety-oriented study, for which the investigators also hypothesize that fluorometholone will have a perioperative safety profile acceptable for large-scale programmatic use. Topical corticosteroid therapy is associated with potential risks of cataract induction and intraocular pressure (IOP) elevation in susceptible individuals. Fluorometholone has lower intraocular penetration than alternative corticosteroids, with correspondingly less IOP-raising effect while still having favorable effects on conjunctival inflammation, and is a low-cost generic drug. Its poor delivery of corticosteroid into the eye itself provides an advantage in this setting, as the major side effects of therapy are the result of intraocular effects, and therapy only is needed to the conjunctiva. However, prior to use in a large-scale trial it is sensible to make sure adverse outcomes are not observed in a substantial number of TT patients in a smaller scale trial. Secondary goals of such a trial are to evaluate alternative topical corticosteroid dosing schedules to identify an optimal dosing schedule and to identify any preliminary signals of potential efficacy.


Clinical Trial Description

Protocol Title: Fluorometholone 0.1% as Perioperative Adjunct Therapy for Lid-rotation Surgery in Trachomatous Entropion and Trichiasis, Dose-varying Study

Study Design: Randomized, double-masked, dose-ranging study of three dose levels of fluorometholone 0.1% or placebo in one eye of subjects with trachomatous trichiasis (TT) undergoing lid rotation surgery

Primary Study Objective: Evaluate the safety and tolerability of three (3) doses of fluorometholone 0.1% in subjects with trachomatous trichiasis (TT) undergoing lid rotation surgery (Bilamellar Tarsal Rotation)

Secondary Study Objective: Conduct a preliminary assessment of the efficacy of three (3) doses of fluorometholone 0.1% in subjects with trachomatous trichiasis (TT) undergoing lid rotation surgery (Bilamellar Tarsal Rotation)

Number of Subjects: Up to 156 eyes of up to 156 subjects

Study Population: Subjects with trachomatous trichiasis (TT) undergoing lid rotation surgery (Bilamellar Tarsal Rotation)

Test Articles:

1. Fluorometholone 0.1% one drop twice daily for four weeks

2. Placebo one drop twice daily for four weeks

3. Fluorometholone 0.1% one drop four times daily for four weeks

4. Placebo one drop four times daily for four weeks

5. Fluorometholone 0.1% one drop four times daily for eight weeks

6. Placebo one drop four times daily for eight weeks

Visit Schedule: Following trichiasis surgery on Day 0, subjects will return for study visits approximately on Days 14, 28, 56, 90, and 365

Tolerability Parameters:

- Treatment-emergent ocular symptoms/signs

- Discontinuation of drug / treatment because of side effects

Safety Parameters:

- Intraocular pressure elevation ≥30 mm Hg

- Cataract

- Adverse events

- Treatment emergent abnormal ophthalmic findings

- Treatment emergent external examination findings

- Visual acuity

Efficacy Parameters:

- Trichiasis recurrence

- Entropion recurrence

- Trachoma activity grade (to the extent activity can be graded in eyes with severe trachomatous scarring) ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01949454
Study type Interventional
Source University of Pennsylvania
Contact
Status Completed
Phase N/A
Start date November 2013
Completion date April 2016

See also
  Status Clinical Trial Phase
Completed NCT03676140 - Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Phase 3
Completed NCT01202331 - Tripartite International Research for the Elimination of Trachoma Phase 4
Completed NCT05634759 - Enhancing the A in SAFE for Trachoma Phase 4
Recruiting NCT04185402 - Azithromycin Reduction to Reach Elimination of Trachoma Phase 4
Active, not recruiting NCT00886015 - Modified Instrumentation for Surgery to Correct Trichiasis Phase 3
Completed NCT00792922 - Partnership for Rapid Elimination of Trachoma Phase 4
Completed NCT00522860 - A Trial of Non-absorbable Versus Absorbable Sutures for Trichiasis Surgery Phase 4
Completed NCT00221364 - Trachoma Elimination Follow-up Phase 4
Completed NCT00322972 - Trachoma Amelioration in Northern Amhara (TANA) Phase 4
Withdrawn NCT00286026 - Azithromycin in Control of Trachoma II Phase 4
Completed NCT00347763 - Effect of Intensive Fly Control on Trachoma and Ocular Chlamydia Infection in Tanzania Phase 4
Terminated NCT04002726 - App-based Versus Slide-based Inter-grader Agreement (IGA) Test for Trachoma Graders N/A
Terminated NCT03997487 - Smartphone App for Taking Images of Conjunctivae N/A
Withdrawn NCT02655432 - Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population Phase 0
Completed NCT01767506 - A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial N/A
Completed NCT00618449 - Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger Phase 4
Completed NCT00356720 - Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% Versus Oral Azithromycin in Treatment of Trachoma Phase 3
Completed NCT03813069 - Testing Insect Repellents Against Musca Sorbens, the Vector of Trachoma Phase 2
Recruiting NCT03335072 - Kebele Elimination of Trachoma for Ocular Health Phase 4
Not yet recruiting NCT06289647 - Azithromycin Reduction to Reach Elimination of Trachoma B Phase 4